Azitra reports Q3 2023 net loss of $1.9M; cash $4.4M; pipeline advances for ATR-12 and ATR-04

Azitra, Inc.

2023-Q3 EPS reported -$1.97 revenue$596,000

Net loss of $1.9M narrowed from $2.4M in Q3 2022; R&D expenses fell to $548,524 from $1.4M.
Cash and cash equivalents of $4.4M as of Sept 30, 2023; service revenue from related party of $310,700.
Lead program ATR-12 (Netherton syndrome) IND cleared; CRO hired; first patient enrollment expected in 2024.
ATR-04 (EGFRi-associated rash) advancing toward IND; upcoming milestones include preclinical data and IND submission.
Bayer joint development agreement progressing; royalty-bearing licensing agreement expected as next step.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Azitra, Inc. reported the fiscal quarter ended September 30, 2023 results: net income $1.9 million.

Period: the fiscal quarter ended September 30, 2023
Net income: $1.9 million
Result: reported results

Exact text from the filing

On November 14, 2023, Azitra, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Azitra, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.